Lataa...
Bevacizumab-induced nasal septal perforation: Incidence of symptomatic, confirmed event(s) in colorectal cancer patients
PURPOSE: In breast cancer patients, Mailliez and others described that 5 of 70 patients (7%) developed a bevacizumab-induced nasal septal perforation. However, to date, no studies have reported such rates in colorectal cancer patients, who derive a survival advantage with this drug. METHODS: This st...
Tallennettuna:
| Julkaisussa: | Acta Oncol |
|---|---|
| Päätekijät: | , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
2010
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6014966/ https://ncbi.nlm.nih.gov/pubmed/21108568 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3109/0284186X.2010.537692 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|